Highlights
- •Early carcinomas/cancer precursor lesions identified in the fallopian tube of BRCA carriers are potential surrogate markers
- •Retrospective prevalence of these early events varies widely due to heterogeneity in the diagnostic methodology used
- •Cancer precursor lesions need to be defined with the rigorous validated procedures
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- BRCA and early events in the development of serous ovarian cancer.Front. Oncol. Jan 23 2014; 4: 5
- Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.Gynecol. Oncol. Feb 2014; 132: 261-263
- Aspirin in prevention of ovarian cancer: are we at the tipping point?.J. Natl. Cancer Inst. Feb 2014; 106: djt453
- Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose).J. Clin. Oncol. Aug 1 2010; 28: 3570-3576
- Risk management options elected by women after testing positive for a BRCA mutation.Gynecol. Oncol. Feb 2014; 132: 428-433
- Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.J. Oncol. 2010; 2010: 126295
- Clinical and pathologic findings of prophylactic salpingo-oophorectomies 159 BRCA1 and BRCA2 carriers.Gynecol. Oncol. 2006; 100: 58-64
- Risk reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.J. Clin. Oncol. 2005; 23: 127-132
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J. Clin. Oncol. 2007; 25: 3985-3990
- Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.Mod. Pathol. Sep 2009; 22: 1133-1138
- Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.Gynecol. Oncol. Sep 2010; 118: 295-298
- Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.Mod. Pathol. Aug 2009; 22: 985-988
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am. J. Surg. Pathol. Feb 2006; 30: 230-236
- Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.Am. J. Surg. Pathol. Dec 2011; 35: 1766-1775
- Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.Int. J. Gynecol. Pathol. May 2012; 31: 243-253
Article info
Publication history
Published online: June 10, 2015
Accepted:
June 8,
2015
Received in revised form:
June 5,
2015
Received:
March 31,
2015
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
